Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain; Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1673-1676. doi: 10.1016/j.cgh.2018.01.047. Epub 2018 Feb 21.
Patients with irritable bowel syndrome (IBS) often associate their symptoms to certain foods. In congenital sucrase-isomaltase deficiency (CSID), recessive mutations in the SI gene (coding for the disaccharidase digesting sucrose and 60% of dietary starch) cause clinical features of IBS through colonic accumulation of undigested carbohydrates, triggering bowel symptoms. Hence, in a previous study, we hypothesized that CSID variants reducing SI enzymatic activity may contribute to development of IBS symptoms. We detected association with increased risk of IBS for 4 rare loss-of-function variants typically found in (homozygous) CSID patients, because carriers (heterozygous) of these rare variants were more common in patients than in controls. Through a 2-step computational and experimental strategy, the present study aimed to determine whether other (dys-)functional SI variants are associated with risk of IBS in addition to known CSID mutations. We first aimed to identify all SI rare pathogenic variants (SI-RPVs) on the basis of integrated Mendelian Clinically Applicable Pathogenicity (M-CAP) and Combined Annotation Dependent Depletion (CADD) predictive (clinically relevant) scores; next, we inspected genotype data currently available for 2207 IBS patients from a large ongoing project to compare SI-RPV case frequencies with ethnically matched population frequencies from the Exome Aggregation Consortium (ExAC).
肠易激综合征(IBS)患者常将其症状与某些食物联系起来。在先天性蔗糖-异麦芽糖酶缺乏症(CSID)中,SI 基因(编码消化蔗糖和 60%膳食淀粉的双糖酶)的隐性突变导致未消化碳水化合物在结肠中积聚,从而引发肠道症状,出现 IBS 的临床特征。因此,在之前的研究中,我们假设降低 SI 酶活性的 CSID 变体可能有助于发展 IBS 症状。我们发现,4 种罕见的无功能变体与 IBS 风险增加相关,这些变体通常存在于(纯合子)CSID 患者中,因为这些罕见变体的携带者(杂合子)在患者中比在对照组中更为常见。通过两步计算和实验策略,本研究旨在确定除了已知的 CSID 突变外,其他(功能障碍)SI 变体是否与 IBS 风险相关。我们首先旨在根据综合 Mendelian 临床可适用性致病性(M-CAP)和联合注释依赖性损耗(CADD)预测(临床相关)评分,确定所有 SI 罕见致病性变体(SI-RPV);接下来,我们检查了来自一个大型正在进行的项目的 2207 名 IBS 患者的基因型数据,以比较 SI-RPV 病例频率与外显子组聚合联盟(ExAC)中种族匹配人群的频率。